Neuroimaging is another potential method with diagnostic utility alone, or as an adjunct to clinical and biofluid biomarkers in FTLD; we have found combining neuropsychological testing and MRI can improve diagnostic accuracy in PPA (Hu et al., 2010c); and others find combination of CSF tau isoform levels and midbrain atrophy improve identification of PSP (Borroni et al., 2010). Here, MAPT is linked to supranuclear palsy, progressive, 1.